On Monday, Trevi Therapeutics Inc (NASDAQ: TRVI) was 5.50% up from the session before settling in for the closing price of $2.91. A 52-week range for TRVI has been $0.97 – $4.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -67.14%. With a float of $49.25 million, this company’s outstanding shares have now reached $68.28 million.
Let’s look at the performance matrix of the company that is accounted for 25 employees. In terms of profitability, gross margin is 38.64%, operating margin of -27394.89%, and the pretax margin is -25196.59%.
Trevi Therapeutics Inc (TRVI) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Trevi Therapeutics Inc stocks. The insider ownership of Trevi Therapeutics Inc is 35.92%, while institutional ownership is 39.25%. The most recent insider transaction that took place on Sep 06 ’24, was worth 12,784. In this transaction President & CEO of this company sold 4,219 shares at a rate of $3.03, taking the stock ownership to the 213,313 shares. Before that another transaction happened on Sep 09 ’24, when Company’s President & CEO sold 1,840 for $3.04, making the entire transaction worth $5,587. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.08 earnings per share (EPS) during the time that was better than consensus figure (set at -0.09) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -67.14% per share during the next fiscal year.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
You can see what Trevi Therapeutics Inc (TRVI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Trevi Therapeutics Inc (NASDAQ: TRVI) saw its 5-day average volume 0.74 million, a positive change from its year-to-date volume of 0.29 million. As of the previous 9 days, the stock’s Stochastic %D was 39.70%. Additionally, its Average True Range was 0.20.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 51.18%, which indicates a significant decrease from 55.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.16% in the past 14 days, which was lower than the 64.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.15, while its 200-day Moving Average is $2.85. Nevertheless, the first resistance level for the watch stands at $3.17 in the near term. At $3.28, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.43. If the price goes on to break the first support level at $2.91, it is likely to go to the next support level at $2.76. Assuming the price breaks the second support level, the third support level stands at $2.65.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
There are 76,866K outstanding shares of the company, which has a market capitalization of 236.79 million. As of now, sales total 0 K while income totals -29,070 K. Its latest quarter income was 0 K while its last quarter net income were -12,350 K.
